{"id":"1a2e5842-5c28-403f-8896-804dce446926","dataset":"sourcesCorporatePublication","time":37,"normalizedUIQL":null,"lastDatasetUpdate":"2019-02-16T00:12:36Z","PagedResults":{"total":1387,"firstRow":1,"lastRow":140,"Result":[{"Field":[{"name":"sourceId","type":"string","value":"177263"},{"name":"corporatePublicationTitle","type":"string","value":"Zynaxis Technologies Part III. Drug delivery technologies - Radiotherapeutic and chemotherapeutic Zyn-Linkers for treatment of cancer &amp; Summary"},{"name":"corporatePublicationType","type":"string","value":"Company Brochure"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1993-05-12T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Zynaxis Technologies"}],"pos":1},{"Field":[{"name":"sourceId","type":"string","value":"1650164"},{"name":"corporatePublicationTitle","type":"string","value":"FDA Orphan Drug Designations and Approvals: Treosulfan (Ovastat); Treatment of ovarian cancer"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1994-05-16T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Food and Drug Administration"}],"pos":2},{"Field":[{"name":"sourceId","type":"string","value":"179936"},{"name":"corporatePublicationTitle","type":"string","value":"Imperial Cancer Research Fund annual review 1993/4"},{"name":"corporatePublicationType","type":"string","value":"Company Brochure"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1994-07-04T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Imperial Cancer Research Fund"}],"pos":3},{"Field":[{"name":"sourceId","type":"string","value":"168288"},{"name":"corporatePublicationTitle","type":"string","value":"Tumor suppressors and gene therapy of cancer"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1994-11-15T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Canji INC"}],"pos":4},{"Field":[{"name":"sourceId","type":"string","value":"168285"},{"name":"corporatePublicationTitle","type":"string","value":"Recombinant human retinoblastoma protein inhibits cancer cell growth"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1994-11-15T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"CANJI INC"}],"pos":5},{"Field":[{"name":"sourceId","type":"string","value":"177863"},{"name":"corporatePublicationTitle","type":"string","value":"'Immortalizing enzyme' detected in many types of cancer, reported in Science Findings support study of telomerase as potential single, specific anti-cancer target"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1994-12-23T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":null}],"pos":6},{"Field":[{"name":"sourceId","type":"string","value":"222422"},{"name":"corporatePublicationTitle","type":"string","value":"Annual Report - Institute of Cancer Research - 1994"},{"name":"corporatePublicationType","type":"string","value":"Annual Report"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1994-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Institute of Cancer Research, UK"}],"pos":7},{"Field":[{"name":"sourceId","type":"string","value":"179932"},{"name":"corporatePublicationTitle","type":"string","value":"No Title"},{"name":"corporatePublicationType","type":"string","value":"Annual Report"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1994-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Cancer Research Campaign (UK)"}],"pos":8},{"Field":[{"name":"sourceId","type":"string","value":"175246"},{"name":"corporatePublicationTitle","type":"string","value":"With a current emphasis on cancer, Cytogen has five products to target specific sites of disease - four in variuos stages of clinical development, and one on the market"},{"name":"corporatePublicationType","type":"string","value":"Company Brochure"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1994-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Cytogen"}],"pos":9},{"Field":[{"name":"sourceId","type":"string","value":"180745"},{"name":"corporatePublicationTitle","type":"string","value":"Avicidin cancer therapy"},{"name":"corporatePublicationType","type":"string","value":"Company Brochure"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1995-02-17T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"NeoRx Corporation"}],"pos":10},{"Field":[{"name":"sourceId","type":"string","value":"175194"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: Remune, AI-208, IR-501, vaccine (colon cancer), IRC/SKCC, GeneDrug, IR-502"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1995-03-15T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"The Immune Response Corporation"}],"pos":11},{"Field":[{"name":"sourceId","type":"string","value":"195137"},{"name":"corporatePublicationTitle","type":"string","value":"Use of CEA-Scan in planning for resection of recurrent and/or metastatic colorectal cancer"},{"name":"corporatePublicationType","type":"string","value":"Company Brochure"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1995-07-03T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Immunomedics Inc"}],"pos":12},{"Field":[{"name":"sourceId","type":"string","value":"182244"},{"name":"corporatePublicationTitle","type":"string","value":"Prospective grant of license: Tumor infiltrating lymphocytes as a treatment modality for human cancer"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1995-07-28T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"National Institutes of Health"}],"pos":13},{"Field":[{"name":"sourceId","type":"string","value":"183391"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: Theragyn"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1995-08-18T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Imperial Cancer Research Technology Ltd"}],"pos":14},{"Field":[{"name":"sourceId","type":"string","value":"183672"},{"name":"corporatePublicationTitle","type":"string","value":"Genes and Breast Cancer. research breakthroughs open up promising new avenues for diagnosis and treatment"},{"name":"corporatePublicationType","type":"string","value":"Company Brochure"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1995-08-24T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Canji Inc"}],"pos":15},{"Field":[{"name":"sourceId","type":"string","value":"189939"},{"name":"corporatePublicationTitle","type":"string","value":"Kinase Inhibitor Program Cancer and Anti-Fungal Therapeutics"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1995-10-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Mitotix Inc"}],"pos":16},{"Field":[{"name":"sourceId","type":"string","value":"189938"},{"name":"corporatePublicationTitle","type":"string","value":"Phosphatase Inhibitors: Cancer/Anti-fungal/Cardiovascular Therapeutics"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1995-10-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Mitotix Inc"}],"pos":17},{"Field":[{"name":"sourceId","type":"string","value":"189935"},{"name":"corporatePublicationTitle","type":"string","value":"Intracellular Proteolysis Program: Cancer and Anti-Inflammatory Therapeutics"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1995-10-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Mitotix Inc"}],"pos":18},{"Field":[{"name":"sourceId","type":"string","value":"193417"},{"name":"corporatePublicationTitle","type":"string","value":"BIOMIRA, Dedicated to the diagnosis and treatment of cancer"},{"name":"corporatePublicationType","type":"string","value":"Company Brochure"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1995-11-30T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Biomira Inc"}],"pos":19},{"Field":[{"name":"sourceId","type":"string","value":"228406"},{"name":"corporatePublicationTitle","type":"string","value":"Annual Report 1995 - Ludwig Institute for Cancer Research (Australia)"},{"name":"corporatePublicationType","type":"string","value":"Annual Report"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1995-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Ludwig Institute for Cancer Research (Australia)"}],"pos":20},{"Field":[{"name":"sourceId","type":"string","value":"200065"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: ImmuRAID-LL1, CEA-Scan, ImmuRAID-AFP-Tc-99m, Immunomedics and ImmuRAID-HCG-Tc-99m, Immunomedics, lymphoScan, sulesomab, AFP-Cide, CEA-Cide, ImmuRAID-HCG(I-131), Immunomedics, ImmuRAIT-LL2, ImmuRAIT-CEA-rhenium-188, Immunomedics, immutox (humanized form), Immunomedics, PCP-Scan, DOX-CEA, rhenium-188-LL2, Immunomedics, vaccine (cancer) (1), Immunomedics"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1996-02-27T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Immunomedics Inc"}],"pos":21},{"Field":[{"name":"sourceId","type":"string","value":"422395"},{"name":"corporatePublicationTitle","type":"string","value":"Breast cancer Clinical trials of a new drug Search which led to the development of EM-800 started at the Molecular Laboratory of Endocrinology in 1992"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1996-02-28T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Universite Laval"}],"pos":22},{"Field":[{"name":"sourceId","type":"string","value":"206111"},{"name":"corporatePublicationTitle","type":"string","value":"Cell Pathways Inc Chemoprevention - a new approach to cancer"},{"name":"corporatePublicationType","type":"string","value":"Company Brochure"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1996-04-12T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Cell Pathways Inc"}],"pos":23},{"Field":[{"name":"sourceId","type":"string","value":"217501"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: ribozymes (cancer), Ribozyme, LY-466700, ribozymes (VEGF), Ribozyme, ProtoGene, ribozymes (osteoarthritis), Ribozyme"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1996-08-28T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Ribozyme Pharmaceuticals Inc"}],"pos":24},{"Field":[{"name":"sourceId","type":"string","value":"220577"},{"name":"corporatePublicationTitle","type":"string","value":"Re: ERIC-1, ICRT"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1996-10-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Imperial Cancer Research Technology Ltd"}],"pos":25},{"Field":[{"name":"sourceId","type":"string","value":"220635"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: vaccine (cancer), Sandoz/Wistar, vaccine (GI tumor), Wistar"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1996-10-02T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":null}],"pos":26},{"Field":[{"name":"sourceId","type":"string","value":"221096"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: gene therapy (cancer), MediGene, CHF therapy, MediGene, antibacterials, MediGene"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1996-10-07T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"MediGene GmbH"}],"pos":27},{"Field":[{"name":"sourceId","type":"string","value":"222486"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: interleukin-2 vaccine"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1996-10-11T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Institute of Cancer Research, UK"}],"pos":28},{"Field":[{"name":"sourceId","type":"string","value":"221892"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: microsponge (tretinoin), colon specific DDS (budesonide), polyorthoester DDS (cancer), Hydrosponge (topical DDS), bioerodible DDS (vaccine), microsponge (gastrointestinal disease), microsponge (periodontal)"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1996-10-14T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Advanced Polymer Systems"}],"pos":29},{"Field":[{"name":"sourceId","type":"string","value":"224278"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: CFGT, GenVec, radition therapy, GenVec, vector technology, Theragen, gene therapy (colon cancer), GenVec, ADGVVEGF121.10, HSV type 1 mutant, BTG"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1996-11-05T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"GenVec Inc"}],"pos":30},{"Field":[{"name":"sourceId","type":"string","value":"228115"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: Abiraterone"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1996-12-10T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Cancer Research Campaign (UK)"}],"pos":31},{"Field":[{"name":"sourceId","type":"string","value":"228668"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: DOX-LL2, Immunomedics, DOX-CEA, CEA-Scan, immunoconjugates (cancer), Immunomedics, ImmunRAIT-HCGI(I-131), Immunomedics"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1996-12-16T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Immunomedics Inc"}],"pos":32},{"Field":[{"name":"sourceId","type":"string","value":"229103"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: antagonist D, ICRF, gene therapy (interleukin-2), ICRF and gene therapy (breast cancer), ICRF"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1996-12-30T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Imperial Cancer Research Technology Ltd"}],"pos":33},{"Field":[{"name":"sourceId","type":"string","value":"255412"},{"name":"corporatePublicationTitle","type":"string","value":"Annual Report 1996 - Memorial Sloan Kettering Cancer Center Institute"},{"name":"corporatePublicationType","type":"string","value":"Annual Report"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1996-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Memorial Sloan Kettering Cancer Center Institute"}],"pos":34},{"Field":[{"name":"sourceId","type":"string","value":"253711"},{"name":"corporatePublicationTitle","type":"string","value":"Annual Report 1996 - Cancer Research Campaign (UK)"},{"name":"corporatePublicationType","type":"string","value":"Annual Report"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1996-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Cancer Research Campaign (UK)"}],"pos":35},{"Field":[{"name":"sourceId","type":"string","value":"236828"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: lung cancer therapy, Cadus, asthma therapy, Cadus"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1997-03-05T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Cadus Pharmaceutical Corp"}],"pos":36},{"Field":[{"name":"sourceId","type":"string","value":"238147"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: gene therapy (cancer), Oxford BioMedica, gene therapy (parkinson disease), Oxford BioMedica, gene therapy (HIV), Oxford BioMedica, gene delivery technology, Oxford BioMedica, retroviral vectors, Oxford BioMedica"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1997-03-13T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Oxford Biomedica Ltd"}],"pos":37},{"Field":[{"name":"sourceId","type":"string","value":"241356"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: EPICOAT cancer vaccine, Axis"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1997-03-21T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Axis Genetics"}],"pos":38},{"Field":[{"name":"sourceId","type":"string","value":"251348"},{"name":"corporatePublicationTitle","type":"string","value":"Novel Human Cancer Antigen of Tyrosinase-Related Proteins 1 and 2 and Genes Encoding Same"},{"name":"corporatePublicationType","type":"string","value":"Company Brochure"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1997-06-23T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"National Institutes of Health"}],"pos":39},{"Field":[{"name":"sourceId","type":"string","value":"261258"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: abciximab, edrecolomab, infliximab, Factor VIIa inhibitor, Corvas, GeneVax vaccine (cancer), Centocor"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1997-08-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Centocor Inc"}],"pos":40},{"Field":[{"name":"sourceId","type":"string","value":"352407"},{"name":"corporatePublicationTitle","type":"string","value":"Breakdown of NCI-identified ovarian cancer clinical trial"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1997-09-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"National Cancer Institute"}],"pos":41},{"Field":[{"name":"sourceId","type":"string","value":"265939"},{"name":"corporatePublicationTitle","type":"string","value":"Development of a vaccine for breast cancer"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1997-10-06T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Medical Innovation Limited"}],"pos":42},{"Field":[{"name":"sourceId","type":"string","value":"265669"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: gene therapy (cancer), IDUN, ICE inhibitors, IDUN, bcl-2 antagonists, IDUN"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1997-10-07T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"IDUN Pharmaceuticals Inc"}],"pos":43},{"Field":[{"name":"sourceId","type":"string","value":"274956"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: Calydon's prostate cancer therapy"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1997-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Calydon Inc"}],"pos":44},{"Field":[{"name":"sourceId","type":"string","value":"280191"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: Suicide gene therapy (cancer), NIH"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1998-03-05T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"National Institutes of Health"}],"pos":45},{"Field":[{"name":"sourceId","type":"string","value":"286036"},{"name":"corporatePublicationTitle","type":"string","value":"Myriad Genetics and Rockefeller University enter into cancer gene agreement"},{"name":"corporatePublicationType","type":"string","value":"Securities and Exchange Commission Form DEF-14"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1998-04-30T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Myriad Genetics Inc"}],"pos":46},{"Field":[{"name":"sourceId","type":"string","value":"292920"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: ASP-05, gene therapy (schizophrenia), gene therapy (pain), gene therapy (cancer), BAY-44-3428, gene discovery (asthma), human growth hormone mimics, Factor Xa inhibitors"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1998-07-30T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Axys Pharmaceuticals Inc"}],"pos":47},{"Field":[{"name":"sourceId","type":"string","value":"504308"},{"name":"corporatePublicationTitle","type":"string","value":"GTx, Inc. and the University of Tennessee Research Corporation have entered into a license agreement in which GTx, Inc. has received an exclusive license for the worldwide rights to patent applications covering methods for preventing prostate carcinogenesis and suppressing or inhibiting prostate cancer"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1998-07-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"GTx Inc"}],"pos":48},{"Field":[{"name":"sourceId","type":"string","value":"293625"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: Phytera and Chiron collaborating to develop cancer therapeutics"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1998-08-07T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Phytera Inc"}],"pos":49},{"Field":[{"name":"sourceId","type":"string","value":"311630"},{"name":"corporatePublicationTitle","type":"string","value":"Company Brochure - Intracel Corp, management of patients with cancer and infectious diseases"},{"name":"corporatePublicationType","type":"string","value":"Company Brochure"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1998-08-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Intracel Corp"}],"pos":50},{"Field":[{"name":"sourceId","type":"string","value":"298816"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: cancer vaccine, Memorial sloane-Kettering/PowderJect"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1998-09-18T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"PowderJect Pharmaceuticals plc"}],"pos":51},{"Field":[{"name":"sourceId","type":"string","value":"301611"},{"name":"corporatePublicationTitle","type":"string","value":"Intratumoral focused chemotherapy. A new weapon against cancer"},{"name":"corporatePublicationType","type":"string","value":"Company Brochure"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1998-10-16T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Matrix Pharmaceutical Inc"}],"pos":52},{"Field":[{"name":"sourceId","type":"string","value":"305625"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: NSC-645306"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1998-11-12T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"National Cancer Institute"}],"pos":53},{"Field":[{"name":"sourceId","type":"string","value":"363966"},{"name":"corporatePublicationTitle","type":"string","value":"Annual Report 1998 - Cancer Prevention Research Program, NCI"},{"name":"corporatePublicationType","type":"string","value":"Annual Report"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1998-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"National Cancer Institute"}],"pos":54},{"Field":[{"name":"sourceId","type":"string","value":"312016"},{"name":"corporatePublicationTitle","type":"string","value":"Leukemia insights newsletter"},{"name":"corporatePublicationType","type":"string","value":"Company Brochure"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1998-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"MD Anderson Cancer Center"}],"pos":55},{"Field":[{"name":"sourceId","type":"string","value":"310892"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: OncoVax-cl, vaccine (colon cancer), Intracel"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1999-01-06T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Jenner Biotherapies Inc"}],"pos":56},{"Field":[{"name":"sourceId","type":"string","value":"313307"},{"name":"corporatePublicationTitle","type":"string","value":"Vaccine created from gene therapy found to be effective in treating ovarian cancer"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1999-02-03T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Tulane University"}],"pos":57},{"Field":[{"name":"sourceId","type":"string","value":"315315"},{"name":"corporatePublicationTitle","type":"string","value":"Dan Mercola's Gene Therapy Program Inhibition of prostate, glioblastoma, lung and breast tumor cell growth"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1999-02-17T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Sidney Kimmel Cancer Center"}],"pos":58},{"Field":[{"name":"sourceId","type":"string","value":"316709"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: PFA prodrugs, Allovectin-7, Leuvectin, gene therapy (cancer), Vical/Corixa, gene therapy (hemophilia), Baxter/Vical"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1999-03-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Vical Inc"}],"pos":59},{"Field":[{"name":"sourceId","type":"string","value":"317978"},{"name":"corporatePublicationTitle","type":"string","value":"NCI Cancer Trials: Anti-angiogenesis inihibitors in clinical trials"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1999-03-12T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"National Cancer Institute"}],"pos":60},{"Field":[{"name":"sourceId","type":"string","value":"318291"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: Norwalk EPVaccine, Axis/Genetics, cholera EPVaccine, Axis/Genetics, E coli EPVaccine, Axis/Genetics, EPICOAT cancer vaccine, Axis, vaccine (S aureus), Axis"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1999-03-16T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Axis Genetics plc"}],"pos":61},{"Field":[{"name":"sourceId","type":"string","value":"318316"},{"name":"corporatePublicationTitle","type":"string","value":"Cancer trials: antiangiogenesis inhibitors in clinical trials"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1999-03-17T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"National Cancer Institute"}],"pos":62},{"Field":[{"name":"sourceId","type":"string","value":"322142"},{"name":"corporatePublicationTitle","type":"string","value":"Combination therapy. F-ddA in combination with stavudine and nelfinavir: A phase I Study."},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1999-04-21T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"National Cancer Institute"}],"pos":63},{"Field":[{"name":"sourceId","type":"string","value":"323575"},{"name":"corporatePublicationTitle","type":"string","value":"Projects: Infectious diseases and cancer"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1999-05-05T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Pierre Fabre SA"}],"pos":64},{"Field":[{"name":"sourceId","type":"string","value":"324407"},{"name":"corporatePublicationTitle","type":"string","value":"Collaborative research: Anti-idiotypic antibodies for the immunotherapy of colo-rectal cancer"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1999-05-10T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Cancer Research Campaign Technology Ltd"}],"pos":65},{"Field":[{"name":"sourceId","type":"string","value":"324989"},{"name":"corporatePublicationTitle","type":"string","value":"General Info"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1999-05-17T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"John Wayne Cancer Institute"}],"pos":66},{"Field":[{"name":"sourceId","type":"string","value":"326151"},{"name":"corporatePublicationTitle","type":"string","value":"PHOTODYNAMIC THERAPY (PDT) IN THE TREATMENT OF CANCER AT ROSWELL PARK CANCER INSTITUTE (RPCI)"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1999-05-27T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Roswell Park Cancer Institute"}],"pos":67},{"Field":[{"name":"sourceId","type":"string","value":"328100"},{"name":"corporatePublicationTitle","type":"string","value":"Cancer drugs"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1999-06-16T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"BTG plc"}],"pos":68},{"Field":[{"name":"sourceId","type":"string","value":"329889"},{"name":"corporatePublicationTitle","type":"string","value":"Developmental Therapeutics Program - Status of Compounds"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1999-06-28T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"National Cancer Institute"}],"pos":69},{"Field":[{"name":"sourceId","type":"string","value":"333851"},{"name":"corporatePublicationTitle","type":"string","value":"Angiogenesis inhibitors in clinical trials"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1999-07-26T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"National Cancer Institute"}],"pos":70},{"Field":[{"name":"sourceId","type":"string","value":"363965"},{"name":"corporatePublicationTitle","type":"string","value":"Prevention Post: an introduction to the research groups: Lung and Upper Aerodigestive Cancer RG"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1999-12-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"National Cancer Institute"}],"pos":71},{"Field":[{"name":"sourceId","type":"string","value":"351213"},{"name":"corporatePublicationTitle","type":"string","value":"Research and Development: GL-331 for cancer"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1999-12-21T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Genelabs Technologies Inc"}],"pos":72},{"Field":[{"name":"sourceId","type":"string","value":"411096"},{"name":"corporatePublicationTitle","type":"string","value":"Annual Research Report 1999 - Institute for Cancer Research"},{"name":"corporatePublicationType","type":"string","value":"Annual Report"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1999-12-30T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Ludwig Institute for Cancer Research"}],"pos":73},{"Field":[{"name":"sourceId","type":"string","value":"459086"},{"name":"corporatePublicationTitle","type":"string","value":"Cancer Therapy: Binary Modes"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2000-01-04T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Weizmann Institute of Science"}],"pos":74},{"Field":[{"name":"sourceId","type":"string","value":"354129"},{"name":"corporatePublicationTitle","type":"string","value":"Angiogenesis inhibitors in clinical trials/Phase I study of PTK787/ZK 222584 in patients with HIV-associated Kaposi's Sarcome"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2000-02-02T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"National Cancer Institute"}],"pos":75},{"Field":[{"name":"sourceId","type":"string","value":"357645"},{"name":"corporatePublicationTitle","type":"string","value":"Univera develops a novel aloe polysaccharide to reduce the risk of skin cancer"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2000-02-29T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Univera Pharmaceuticals Inc"}],"pos":76},{"Field":[{"name":"sourceId","type":"string","value":"357795"},{"name":"corporatePublicationTitle","type":"string","value":"Biomodulation to enhance cancer chemotherapy"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2000-03-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Biokeys Pharmaceuticals Inc"}],"pos":77},{"Field":[{"name":"sourceId","type":"string","value":"357769"},{"name":"corporatePublicationTitle","type":"string","value":"Organoselones in Cancer Chemotherapy"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2000-03-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Biokeys Pharmaceuticals Inc"}],"pos":78},{"Field":[{"name":"sourceId","type":"string","value":"361663"},{"name":"corporatePublicationTitle","type":"string","value":"Cytoclonal Pharmaceuticals: technology/human gene program/lung cancer gene"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2000-04-06T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Cytoclonal Pharmaceutics Inc"}],"pos":79},{"Field":[{"name":"sourceId","type":"string","value":"361842"},{"name":"corporatePublicationTitle","type":"string","value":"IDN-5109, a new taxane for the fight against cancer"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2000-04-07T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Idena SpA"}],"pos":80},{"Field":[{"name":"sourceId","type":"string","value":"363537"},{"name":"corporatePublicationTitle","type":"string","value":"NCI Cancer Trials: Anti-angiogenesis inihibitors in clinical trials"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2000-04-19T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"National Cancer Institute"}],"pos":81},{"Field":[{"name":"sourceId","type":"string","value":"364908"},{"name":"corporatePublicationTitle","type":"string","value":"Intracel BCI-immuneactivator for the treatment of bladder cancer"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2000-05-03T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Intracel Corp"}],"pos":82},{"Field":[{"name":"sourceId","type":"string","value":"490848"},{"name":"corporatePublicationTitle","type":"string","value":"Fenretinide to Prevent Cancer Recurrence in Treating Patients With Bladder Cancer"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2000-07-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"National Institutes of Health"}],"pos":83},{"Field":[{"name":"sourceId","type":"string","value":"379239"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: diabetes therapeutics, OP-1, Chondrogel, Neo-bladder, Vascugel, skin cancer therapy (basal cell carcinoma), hedgehog proteins"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2000-08-16T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Curis Inc"}],"pos":84},{"Field":[{"name":"sourceId","type":"string","value":"382475"},{"name":"corporatePublicationTitle","type":"string","value":"Ventures. RCT/GWU developing imaging agent for lung and breast cancers, melanoma"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2000-09-16T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Research Corp Technologies Inc"}],"pos":85},{"Field":[{"name":"sourceId","type":"string","value":"387697"},{"name":"corporatePublicationTitle","type":"string","value":"AltaRex - Changing the course of cancer therapy"},{"name":"corporatePublicationType","type":"string","value":"Company Brochure"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2000-09-27T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"AltaRex Corp"}],"pos":86},{"Field":[{"name":"sourceId","type":"string","value":"384946"},{"name":"corporatePublicationTitle","type":"string","value":"Independent comment on L-778123"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2000-10-05T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Cancer Institute New Jersey"}],"pos":87},{"Field":[{"name":"sourceId","type":"string","value":"422291"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: ovarian cancer therapy, Atairgin"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2000-11-14T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Atairgin Technologies Inc"}],"pos":88},{"Field":[{"name":"sourceId","type":"string","value":"430811"},{"name":"corporatePublicationTitle","type":"string","value":"Gene-based cancer vaccine"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2000-11-29T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Oxford BioMedica"}],"pos":89},{"Field":[{"name":"sourceId","type":"string","value":"391843"},{"name":"corporatePublicationTitle","type":"string","value":"Independent comment on LG-370020, BMS-207977 and CP-347589"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2000-11-29T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"H Lee Moffitt Cancer Center & Research Institute"}],"pos":90},{"Field":[{"name":"sourceId","type":"string","value":"422323"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: macrocyclic taxoids, SUNY/Roswell Park Cancer Institute"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2000-12-07T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"State University of New York Stony Brook"}],"pos":91},{"Field":[{"name":"sourceId","type":"string","value":"422245"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: drug discovery (cancer), VIMRx/Columbia University"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2000-12-10T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Columbia University"}],"pos":92},{"Field":[{"name":"sourceId","type":"string","value":"394017"},{"name":"corporatePublicationTitle","type":"string","value":"Seattle Genetics mAbs for cancer: lead agents"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2000-12-18T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Seattle Genetics Inc"}],"pos":93},{"Field":[{"name":"sourceId","type":"string","value":"396524"},{"name":"corporatePublicationTitle","type":"string","value":"The Cancer Institute of New Jersey. Active clinical trials as of 12/14/2000"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2001-01-22T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"University of Medicine and Dentistry of New Jersey"}],"pos":94},{"Field":[{"name":"sourceId","type":"string","value":"405992"},{"name":"corporatePublicationTitle","type":"string","value":"Antibodies to urothelial apical surface antigens for the detection, classification and treatment of bladder cancer"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2001-04-18T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":null}],"pos":95},{"Field":[{"name":"sourceId","type":"string","value":"408572"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline - SU-6668"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2001-05-10T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Cancer Research Campaign"}],"pos":96},{"Field":[{"name":"sourceId","type":"string","value":"409225"},{"name":"corporatePublicationTitle","type":"string","value":"Pipeline opportunities: non-cancer programs: Flk-1/KDR in opthalmology"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2001-05-16T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"SUGEN Inc"}],"pos":97},{"Field":[{"name":"sourceId","type":"string","value":"432574"},{"name":"corporatePublicationTitle","type":"string","value":"Oncology/immune disorders: cancer vaccine"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2001-05-29T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"QLT Inc"}],"pos":98},{"Field":[{"name":"sourceId","type":"string","value":"411264"},{"name":"corporatePublicationTitle","type":"string","value":"Rebeccamycin analog"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2001-05-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"National Cancer Institute"}],"pos":99},{"Field":[{"name":"sourceId","type":"string","value":"411738"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline - mitoflaxone"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2001-06-06T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Cancer Research Campaign Technology Ltd"}],"pos":100},{"Field":[{"name":"sourceId","type":"string","value":"413538"},{"name":"corporatePublicationTitle","type":"string","value":"SU-6668 - phase I trial at the Royal Marsden Hospital, UK"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2001-06-12T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Cancer Research Campaign"}],"pos":101},{"Field":[{"name":"sourceId","type":"string","value":"411650"},{"name":"corporatePublicationTitle","type":"string","value":"Products in development - Theragyn (pemtumomab) and ovarian cancer"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2001-06-30T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Antisoma Inc"}],"pos":102},{"Field":[{"name":"sourceId","type":"string","value":"414664"},{"name":"corporatePublicationTitle","type":"string","value":"Corixa Corp product pipeline: cancer: Her2/neu for breast and ovarian cancer"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2001-07-06T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Corixa Corp"}],"pos":103},{"Field":[{"name":"sourceId","type":"string","value":"428985"},{"name":"corporatePublicationTitle","type":"string","value":"Programs; Cancer, Angiogenesis, Inflammation, CNS, Metabolism"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2001-07-10T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Exelixis Inc"}],"pos":104},{"Field":[{"name":"sourceId","type":"string","value":"415876"},{"name":"corporatePublicationTitle","type":"string","value":"Clinical trials: allogenic whole cell vaccines: colorectal cancer"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2001-07-17T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Onyvax Ltd"}],"pos":105},{"Field":[{"name":"sourceId","type":"string","value":"416724"},{"name":"corporatePublicationTitle","type":"string","value":"R&amp;D: 6 programs/new vaccines/AIDS/immunotherapy/cancer"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2001-07-24T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Aventis Pasteur SA"}],"pos":106},{"Field":[{"name":"sourceId","type":"string","value":"416888"},{"name":"corporatePublicationTitle","type":"string","value":"Cancer Therapeutics- Variagenic Targeting"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2001-07-26T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Variagenics Inc"}],"pos":107},{"Field":[{"name":"sourceId","type":"string","value":"417249"},{"name":"corporatePublicationTitle","type":"string","value":"Product pipeline: therapeutic vaccines for cancer - other cancer vaccines"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2001-07-30T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Therion Biologics Corp"}],"pos":108},{"Field":[{"name":"sourceId","type":"string","value":"420394"},{"name":"corporatePublicationTitle","type":"string","value":"Phase II trial of ISIS-2503 in patients with non-small cell lung cancer (NSCLC)"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2001-08-28T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"ISIS Pharmaceuticals Inc"}],"pos":109},{"Field":[{"name":"sourceId","type":"string","value":"420391"},{"name":"corporatePublicationTitle","type":"string","value":"Phase II trials of ISIS-2503 in patients with advanced pancreatic cancer"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2001-08-28T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"ISIS Pharmaceuticals"}],"pos":110},{"Field":[{"name":"sourceId","type":"string","value":"422212"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: p16/p53 gene therapy, gene therapy (pancreatic cancer), gene therapy (obesity), AdCMV.CD"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2001-09-11T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Merck Inc"}],"pos":111},{"Field":[{"name":"sourceId","type":"string","value":"422853"},{"name":"corporatePublicationTitle","type":"string","value":"Antibody therapies: the use of tumor-targeting monoclonal antibodies in molecular imaging and radioimmunotherapy"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2001-09-24T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Ludwig Institute for Cancer Research"}],"pos":112},{"Field":[{"name":"sourceId","type":"string","value":"427636"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: cancer therapy, ARIUS"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2001-11-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"ARIUS Research Inc"}],"pos":113},{"Field":[{"name":"sourceId","type":"string","value":"430151"},{"name":"corporatePublicationTitle","type":"string","value":"Product pipeline: cancer and angiogenesis"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2001-11-22T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Exelixis Inc"}],"pos":114},{"Field":[{"name":"sourceId","type":"string","value":"430471"},{"name":"corporatePublicationTitle","type":"string","value":"Breast cancer"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2001-11-23T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"SignalGene Inc"}],"pos":115},{"Field":[{"name":"sourceId","type":"string","value":"1363104"},{"name":"corporatePublicationTitle","type":"string","value":"CAMPTOSAR + 5-FU/LV FOR FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER: A POST-MARKETING REEVALUATION OF SAFETY"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2001-11-25T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Food and Drug Administration"}],"pos":116},{"Field":[{"name":"sourceId","type":"string","value":"432716"},{"name":"corporatePublicationTitle","type":"string","value":"InformedInvestors.com Virtual Cancer Stocks Forum"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2001-12-04T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Genentech Inc"}],"pos":117},{"Field":[{"name":"sourceId","type":"string","value":"433988"},{"name":"corporatePublicationTitle","type":"string","value":"Annual Report 2000/2001: CRC Experimental Cancer Chemotherapy Research Group, School of Pharmaceutical Sciences, University of Nottingham"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2001-12-18T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"University of Nottingham"}],"pos":118},{"Field":[{"name":"sourceId","type":"string","value":"490599"},{"name":"corporatePublicationTitle","type":"string","value":"NY-ESO-1 in the clinic"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2001-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Ludwig Institute for Cancer Research"}],"pos":119},{"Field":[{"name":"sourceId","type":"string","value":"490400"},{"name":"corporatePublicationTitle","type":"string","value":"New York Research"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2001-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Ludwig Institute for Cancer Research"}],"pos":120},{"Field":[{"name":"sourceId","type":"string","value":"435141"},{"name":"corporatePublicationTitle","type":"string","value":"Aventis Pasteur's cancer vaccine program"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-01-08T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Aventis Pasteur SA"}],"pos":121},{"Field":[{"name":"sourceId","type":"string","value":"435657"},{"name":"corporatePublicationTitle","type":"string","value":"Company profile"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-01-14T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Australian Cancer Technology Ltd"}],"pos":122},{"Field":[{"name":"sourceId","type":"string","value":"435655"},{"name":"corporatePublicationTitle","type":"string","value":"Developing healthier futures"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-01-14T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Australian Cancer Technology Ltd"}],"pos":123},{"Field":[{"name":"sourceId","type":"string","value":"440139"},{"name":"corporatePublicationTitle","type":"string","value":"Therapy development: New therapies"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-02-18T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Cancer Research UK"}],"pos":124},{"Field":[{"name":"sourceId","type":"string","value":"441377"},{"name":"corporatePublicationTitle","type":"string","value":"Cancer Research Campaign Technology Limited: Key Patrners and Start-ups"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-02-25T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Cancer Research Campaign Technology Ltd"}],"pos":125},{"Field":[{"name":"sourceId","type":"string","value":"441079"},{"name":"corporatePublicationTitle","type":"string","value":"Cancer Research Ventures: About us"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-02-25T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Cancer Research Ventures Ltd"}],"pos":126},{"Field":[{"name":"sourceId","type":"string","value":"490851"},{"name":"corporatePublicationTitle","type":"string","value":"Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-03-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"National Institutes of Health"}],"pos":127},{"Field":[{"name":"sourceId","type":"string","value":"441835"},{"name":"corporatePublicationTitle","type":"string","value":"Antineoplastons"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-03-02T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"National Cancer Institute"}],"pos":128},{"Field":[{"name":"sourceId","type":"string","value":"442488"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: Therapeutics (cancer, hypercholesterolemia, HIV), Samaritan"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-03-05T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Samaritan Pharmaceuticals Inc"}],"pos":129},{"Field":[{"name":"sourceId","type":"string","value":"442162"},{"name":"corporatePublicationTitle","type":"string","value":"Products: Cancer Immunotherapies"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-03-05T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Remedyne"}],"pos":130},{"Field":[{"name":"sourceId","type":"string","value":"443404"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: oltipraz"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-03-12T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Fox Chase Cancer Center"}],"pos":131},{"Field":[{"name":"sourceId","type":"string","value":"443512"},{"name":"corporatePublicationTitle","type":"string","value":"Cancer products"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-03-14T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Progenics Pharmaceuticals Inc"}],"pos":132},{"Field":[{"name":"sourceId","type":"string","value":"445419"},{"name":"corporatePublicationTitle","type":"string","value":"Inhaled cancer therapy"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-03-20T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Battelle Pulmonary Therapeutics"}],"pos":133},{"Field":[{"name":"sourceId","type":"string","value":"444671"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: cancer vaccine"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-03-25T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"ApoImmune Inc"}],"pos":134},{"Field":[{"name":"sourceId","type":"string","value":"460461"},{"name":"corporatePublicationTitle","type":"string","value":"Information for shareholders on the progress of the Canadian cancer pain trial"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-03-27T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"International Wex Technologies Inc"}],"pos":135},{"Field":[{"name":"sourceId","type":"string","value":"453175"},{"name":"corporatePublicationTitle","type":"string","value":"Pipeline: therapeutic areas: cancer"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-04-13T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Celltech Group plc"}],"pos":136},{"Field":[{"name":"sourceId","type":"string","value":"447916"},{"name":"corporatePublicationTitle","type":"string","value":"Breast cancer vaccine"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-04-16T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Vaccinex Inc"}],"pos":137},{"Field":[{"name":"sourceId","type":"string","value":"475716"},{"name":"corporatePublicationTitle","type":"string","value":"MinoVac breast cancer vaccines"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-05-10T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"BioLife Science Forschungs- und Entwicklungsges mbH"}],"pos":138},{"Field":[{"name":"sourceId","type":"string","value":"475701"},{"name":"corporatePublicationTitle","type":"string","value":"Hervac breast cancer vaccines"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-05-10T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"BioLife Science Forschungs- und Entwicklungsges mbH"}],"pos":139},{"Field":[{"name":"sourceId","type":"string","value":"475695"},{"name":"corporatePublicationTitle","type":"string","value":"BioLife Science -Vaccines for prevention and treatment of cancer"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-05-10T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"BioLife Science Forschungs- und Entwicklungsges mbH"}],"pos":140}]},"DatasetCounts":[],"HitTerms":{"Term":[{"value":"cancer"}],"Synonym":[{"value":"cancers"},{"value":"chemotherapy resistant tumor"},{"value":"malignant neoplastic disease"},{"value":"refractory pediatric cancer"}]},"serviceExecutionTime":49}